ES2660372T8 - Sustancias y procedimientos para la utilización en la prevención y/o el tratamiento en la enfermedad de Huntington - Google Patents

Sustancias y procedimientos para la utilización en la prevención y/o el tratamiento en la enfermedad de Huntington

Info

Publication number
ES2660372T8
ES2660372T8 ES15736262T ES15736262T ES2660372T8 ES 2660372 T8 ES2660372 T8 ES 2660372T8 ES 15736262 T ES15736262 T ES 15736262T ES 15736262 T ES15736262 T ES 15736262T ES 2660372 T8 ES2660372 T8 ES 2660372T8
Authority
ES
Spain
Prior art keywords
huntington
procedures
disease
prevention
substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15736262T
Other languages
English (en)
Other versions
ES2660372T3 (es
Inventor
Oskar Smrzka
Stefan Bartl
Michela Parth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affiris AG
Original Assignee
Affiris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris AG filed Critical Affiris AG
Application granted granted Critical
Publication of ES2660372T3 publication Critical patent/ES2660372T3/es
Publication of ES2660372T8 publication Critical patent/ES2660372T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • External Artificial Organs (AREA)
ES15736262.5T 2014-07-10 2015-07-10 Sustancias y procedimientos para la utilización en la prevención y/o el tratamiento en la enfermedad de Huntington Active ES2660372T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14176609 2014-07-10
EP14176609 2014-07-10
PCT/EP2015/065795 WO2016005547A1 (en) 2014-07-10 2015-07-10 Substances and methods for the use in prevention and/or treatment in huntington's disease

Publications (2)

Publication Number Publication Date
ES2660372T3 ES2660372T3 (es) 2018-03-22
ES2660372T8 true ES2660372T8 (es) 2019-02-12

Family

ID=51162585

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15736262.5T Active ES2660372T3 (es) 2014-07-10 2015-07-10 Sustancias y procedimientos para la utilización en la prevención y/o el tratamiento en la enfermedad de Huntington

Country Status (9)

Country Link
US (4) US10053518B2 (es)
EP (1) EP3166660B1 (es)
JP (1) JP2017523165A (es)
CN (1) CN106687475A (es)
AU (1) AU2015286606A1 (es)
DK (1) DK3166660T3 (es)
ES (1) ES2660372T3 (es)
PL (1) PL3166660T3 (es)
WO (1) WO2016005547A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016016278A2 (en) * 2014-07-29 2016-02-04 Neurimmune Holding Ag Human-derived anti-huntingtin (htt) antibodies and uses thereof
CN110156890B (zh) * 2019-04-09 2021-02-02 苏州大学 Semaphorin7A单克隆抗体及其在制备用于治疗炎症疾病药物方面的应用
CN116535510B (zh) * 2023-06-30 2023-11-10 四川省医学科学院·四川省人民医院 一种抗人pla2r的抗体、试剂盒及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375194B2 (en) 2002-01-28 2008-05-20 California Institute Of Technology Antibodies that bind to an epitope on the Huntington's disease protein
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
US7611712B2 (en) * 2003-10-23 2009-11-03 Nelson M. Karp Immunogenic compositions capable of eliciting Th1 immune responses comprising an HIV-1 MA myristate binding site polypeptide
EP2086573B1 (en) * 2006-10-09 2020-11-25 Neurofluidics, Inc. Cerebrospinal fluid purification system
AU2012241648B2 (en) * 2011-04-12 2016-11-17 Centre National De La Recherche Scientifique (Cnrs) Therapeutic peptides and use thereof against Huntington's disease

Also Published As

Publication number Publication date
AU2015286606A1 (en) 2017-01-12
WO2016005547A1 (en) 2016-01-14
PL3166660T3 (pl) 2018-07-31
CN106687475A (zh) 2017-05-17
EP3166660A1 (en) 2017-05-17
JP2017523165A (ja) 2017-08-17
EP3166660B1 (en) 2017-12-13
ES2660372T3 (es) 2018-03-22
US20210040236A1 (en) 2021-02-11
US10053518B2 (en) 2018-08-21
US20220073650A1 (en) 2022-03-10
US20180327513A1 (en) 2018-11-15
DK3166660T3 (en) 2018-02-05
US20170145117A1 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
IL281793A (en) Use of cannabinoids in the treatment of epilepsy
GB2568809B (en) Use of cannabinoids in the treatment of epilepsy
GB2568471B (en) Use of cannabinoids in the treatment of epilepsy
PL3157511T3 (pl) Zastosowanie kannabinoidów w leczeniu padaczki
IL274769A (en) Use of cannabinoids in the treatment of epilepsy
ES2769863T8 (es) 7-hidroxi-cannabidivarín (7-OH-CBDV) para usar en el tratamiento de la epilepsia
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
IL253872B (en) Unnatural semaphorins 3 and their medicinal use
DK2945642T3 (da) Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme
GB201515986D0 (en) Use of cannabinoids in the treatment of mental disorders
IL251530A0 (en) Use of cannabinoids in the treatment of skeletal muscle atrophy
LT3722291T (lt) Indolino junginiai ir jų panaudojimas fibrozinių ligų gydymui
IL281585B (en) Selenogalactoside compounds for the prevention and treatment of galectin-related diseases and their use
GB2564459B (en) Use of cannabinoids in the treatment of a neurodegenerative disease or disorder
DK3153511T3 (da) 2-acylaminothiazolderivat til anvendelse i forebyggelsen eller behandlingen af blære- og urinvejssygdomme
CL2015000537A1 (es) Siarn y su uso en los métodos y composiciones para el tratamiento y/o prevención de enfermedades de los ojos.
GB201504387D0 (en) Materials and methods for the treatment of vascular disease
ES2660372T8 (es) Sustancias y procedimientos para la utilización en la prevención y/o el tratamiento en la enfermedad de Huntington
FI20145861A (fi) Multivalentteja yhdisteitä käytettäväksi aivovaurion hoidossa ja estämisessä
SG11201706819RA (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease
EP3110453A4 (en) Tmem100 peptides and variants thereof and their use in treating or preventing diseases or conditions
PL3015109T3 (pl) Bariera biologiczna z simetikonem do zastosowania w leczeniu zakażeń nosowo-gardłowo-przewodowych
ES1161385Y (es) Dispositivo para la extracción y/o manipulación de células, fluidos y tejidos humanos
TH1601003560A (th) การใช้ของ par-1 แอนทาโกนิสต์ สำหรับการป้องกันและ/หรือการบำบัดสภาวะ ทางพยาธิวิทยาเชิงการทำหน้าที่ของอุ้งเชิงกราน-ฝีเย็บ
TH182881B (th) องค์ประกอบสำหรับการใช้ในการบำบัดภาวะภูมิแพ้